CTOR
Citius Oncology Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$0.56
+0.00 -1.10%
시티어스 온콜로지(CTOR) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$52M
스몰캡
P/E
-
배당수익률
없음
52주 위치
3%
저점 +13% · 고점 -77%
애널리스트
적극 매수
D
Fundamental health
vs. Drug Manufacturers - Specialty & Generic 초소형주· based on 3 axes
수익성 산출 불가 (적자)
성장 Top 68%
밸류에이션 Top 53%
재무 안정 Top 87%
| Index | - | P/E | - | EPS (ttm) | -0.47 | Insider Own | 71.95% | Shs Outstand | 93.0M | Perf Week | -2.46% |
| Market Cap | 0.05B | Forward P/E | 5.56 | EPS next Y | 119.23% | Insider Trans | - | Shs Float | 26.1M | Perf Month | -15.76% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.04 | Inst Own | 15.32% | Short Float | 1.4% | Perf Quarter | -36.61% |
| Income | -0.04B | P/S | 9.21 | EPS this Y | -52.94% | Inst Trans | 4.09% | Short Ratio | 5.14 | Perf Half Y | -50.8% |
| Sales | 0.01B | P/B | 1.47 | EPS next 5Y | - | ROA | -44.25% | Short Interest | 0.37M | Perf YTD | -44.4% |
| Book/sh | 0.38 | P/C | 19.66 | EPS past 3/5Y | - -309.67% | ROE | -119.9% | 52W High | -76.63% ($2.38) | Perf Year | -71.78% |
| Cash/sh | 0.03 | P/FCF | - | Sales past 3/5Y | - | ROIC | -108.81% | 52W Low | 13.19% ($0.49) | Perf 3Y | -94.77% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -144.8% | Gross Margin | 49.42% | Volatility(W/M) | 19.28% 10.07% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 9.42 | Sales Y/Y TTM | - | Oper. Margin | -775.6% | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.12 | EPS Q/Q | -146.07% | Profit Margin | -757.57% | RSI (14) | 33.73 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.5 | Sales Q/Q | - | SMA20 | -15.19% ($0.66) | Beta | 3.51 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/5/15 | SMA50 | -22.96% ($0.73) | Rel Volume | 0.46 | Prev Close | $0.56 |
| Employees | - | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | -2600% -76.17% | SMA200 | -45.69% ($1.03) | Avg Volume(3M) | 0.07M | Price | $0.56 |
| IPO | 2022/12/8 | Option/Short | No/Yes | Trades | 205 | Volume | 32,605 | Change | -1.1% |
Quarterly earnings trend SEC filings · USD
23.12
24.3
24.6
24.12
25.3
25.6
25.12
26.3
Revenue Net income 최근 분기: 매출 $2M · 순이익 $-27M (YoY -244%)
Citius Oncology Inc (CTOR) Investment Analysis
What kind of company is Citius Oncology Inc?
시티어스 온콜로지(CTOR)
Healthcare · Drug Manufacturers - Specialty & Generic
Small-Cap — Low Volume, High Volatility
🧬 A U.S.-based specialty pharmaceutical company developing and commercializing innovative immuno-oncology treatments for rare hematologic cancers. Through its recently FDA-approved therapy 'LYMPHIR™', the company is delivering a next-generation treatment alternative for patients with refractory cutaneous T-cell lymphoma (CTCL).
Learn more about Citius Oncology Inc →Market Cap
$0.1B
Approx. KRW 0.1 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank4900
IPO2022/12/08
Current Price$0.56 ≈ 767원
Key Events
⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 15일 (금) · 장 마감 후 EPS -2600.0% 매출 -76.2%
🔔 Earnings release 2026년 2월 13일 (금) · 장 시작 전 매출 -9.8%
Is it profitable?
Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-775.6%
✓ 적자
Net Margin
Share of revenue left after taxes and interest are paid
-757.6%
✓ 적자
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
49.4%
✓ 양호
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-119.9%
✓ 적자
ROA
Annual earnings relative to total company assets
-44.3%
✓ 적자
ROIC
Return generated per dollar invested in the business
-108.8%
✓ 적자
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.11
✓ Healthy debt
Current Ratio
Liquid assets available to cover liabilities due within a year
0.50
✓ 매우 부진
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.12
✓ 위험
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$4.00
현재가 대비 +614.3%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
5.56배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
내년 EPS 예상 성장률
+119.2%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-1325.0%
평균 서프라이즈
2026.05.15
하회
실적 $-0.27 · 예상 $-0.01 -2600.0%
2026.02.13
하회
실적 $-0.06 · 예상 $-0.04 -50.0%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-52.9%
부진
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+119.2%
우수
📊 How much has it grown? (actual results)
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-309.7%
매우 부진
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Underperformed the market by 88%p over the past year
CTOR -71.8% · S&P 500 +16.0%
Excess return vs. market (price-based, ex-dividends)
1-year basis
vs S&P 500
-87.8%p
Significantly behind the market
vs Health Care (XLV)
-91.5%p
Significantly behind the sector average
Rank among peers
1-year return Bottom 23% Based on 36 peers
Current position within 52-week range
Low (-13.2%p) High (-76.6%p)
Current price is 13.2% above the 52-week low and 76.6% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-59.8%
Annualized volatility
85.0%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-27
Downtrend zone
Current price $0.56 below the midline ($0.66). Normal downward flow. Below the Ichimoku cloud (bearish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-27
Bearish momentum holding
MACD -0.043 < Signal -0.033 in negative zone + Hist negative (-0.010). Weakness in progress.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-27
Bearish zone
RSI 34.2 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 22.7.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
In line with the industry average
Cheap on Vs. Earnings, Pricey on Vs. Sales, In line with peers on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Earnings Cheap
Vs. Assets Mid-range
Vs. Sales Pricey
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
5.56x
✓ Very cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.47x
✓ Fair
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
9.21x
✓ Pricey
Analyst target price (reference)
$4.00 vs. current price +614.3%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic
Who owns it?
Ownership flow is positive
Institutional net buying +4.1% · Short interest light 1.4% · Short interest fell -4.5%p over the last 90 days
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+4.1%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 15.3%
Retail-led
🧑💼 Insiders 72.0%
Founder/management large holders (strong skin-in-the-game)
👤 Retail investors (estimated) 12.7%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.4%
Low — limited short-side pressure
Past 90 days 📉 -4.5%p decrease
Short interest days to cover
5.1 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 93.0M주
Float (tradable shares) 26.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding CTOR
ETFs with the highest weightings · 3 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| CTOR This Stock | $51.7M | - | 1.5 ▲ | -119.9% ▼ | - | -1.1% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
Derivative ETFs for CTOR
Leveraged, inverse, and covered call ETFs based on the underlying asset
12 derivative ETFs based on CTOR (Leverage 8 · Inverse 2 · Covered Call 2)
These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.
ℹ️ What is a Derivative ETF?
These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.
⚠️ Caution: Long-Term Holding
Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.
Leverage 8 ETFs that move 2-3x with CTOR (high volatility)
SOXL
Direxion Daily Semiconductor Bull 3X ETF
-6.33%
$19.9B
USD
ProShares Ultra Semiconductors 2X Shares
-6.47%
$2.6B
SEMY
GraniteShares YieldBOOST Semiconductor ETF
-0.49%
$78M
TSXU
Direxion Daily Semiconductors Top 5 Bull 2X ETF
-5.61%
$14M
DRAL
Defiance Daily Target 2X Long DRAM ETF
-3.10%
$10M
EUVX
Corgi Lithography & Semiconductor Photonics 2x Daily ETF
-5.15%
$3M
TSXD
Direxion Daily Semiconductors Top 5 Bear 2X ETF
+6.09%
$1M
XSEM
Corgi U.S. Semiconductors 2x Daily ETF
-4.17%
Inverse 2 Profits when CTOR falls (downside bet)
Covered Call & Options 2 A strategy that generates monthly dividend income through covered calls
FAQ
What kind of company is 시티어스 온콜로지(CTOR)?
시티어스 온콜로지(CTOR) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CTOR?
The market cap of CTOR is approximately $52M, ranking 4,900 within its sector.
What is the 52-week high and low for CTOR?
CTOR has recorded a 52-week high of $2.38 and a low of $0.49.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.